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Background: As part of the civil aviation safety program to define the adverse effects of ethanol on flying
performance, we performed a DNA microarray analysis of human whole blood samples from a five-time point study
of subjects administered ethanol orally, followed by breathalyzer analysis, to monitor blood alcohol concentration
(BAC) to discover significant gene expression changes in response to the ethanol exposure.
Methods: Subjects were administered either orange juice or orange juice with ethanol. Blood samples were taken
based on BAC and total RNA was isolated from PaxGene™ blood tubes. The amplified cDNA was used in microarray
and quantitative real-time polymerase chain reaction (RT-qPCR) analyses to evaluate differential gene expression.
Microarray data was analyzed in a pipeline fashion to summarize and normalize and the results evaluated for
relative expression across time points with multiple methods. Candidate genes showing distinctive expression
patterns in response to ethanol were clustered by pattern and further analyzed for related function, pathway
membership and common transcription factor binding within and across clusters. RT-qPCR was used with
representative genes to confirm relative transcript levels across time to those detected in microarrays.
Results: Microarray analysis of samples representing 0%, 0.04%, 0.08%, return to 0.04%, and 0.02% wt/vol BAC
showed that changes in gene expression could be detected across the time course. The expression changes were
verified by qRT-PCR.
The candidate genes of interest (GOI) identified from the microarray analysis and clustered by expression pattern
across the five BAC points showed seven coordinately expressed groups. Analysis showed function-based
networks, shared transcription factor binding sites and signaling pathways for members of the clusters. These
include hematological functions, innate immunity and inflammation functions, metabolic functions expected of
ethanol metabolism, and pancreatic and hepatic function. Five of the seven clusters showed links to the p38
MAPK pathway.
Conclusions: The results of this study provide a first look at changing gene expression patterns in human blood
during an acute rise in blood ethanol concentration and its depletion because of metabolism and excretion, and
demonstrate that it is possible to detect changes in gene expression using total RNA isolated from whole blood.
The analysis approach for this study serves as a workflow to investigate the biology linked to expression changes
across a time course and from these changes, to identify target genes that could serve as biomarkers linked to
pilot performance.
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As part of civil aviation safety research into aeromedical
factors impacting flight safety, we have undertaken a
time course study on the effects of acute ethanol expos-
ure to the legal intoxication level of blood alcohol con-
centration (BAC), 0.08 g/dL (0.08% wt/vol), on human
gene expression in non-chronic users. This is a novel
study to identify gene expression patterns in whole
blood messenger RNA and discover biomarkers linked
to BAC.
Mandatory ethanol testing was implemented for U.S.
commercial pilots in 1995. For the period 1995–2000
alcohol violations, occurrences of an alcohol level ex-
ceeding the Federal Aviation Administration (FAA)
limit of ≥0.04%, were attributed to 0.13% of fatal avi-
ation accidents [1]. This number suggests that alcohol
misuse is a relatively rare occurrence in the commercial
aviation setting. To date, alcohol has not been impli-
cated as the probable cause in any fatal crash involving
a U.S. major airline; however, there are instances of
commercial pilots reporting for duty impaired with
BAC ≥0.04% [2,3].
The current FAA regulations prohibit anyone from
acting as a crewmember within eight hours of consum-
ing alcohol or while having a BAC ≥0.04%. However, a
number of reports addressing the carry-over effect of al-
cohol have shown a performance loss to remain after the
BAC has returned to less than 0.02% [4]. Communica-
tion performance decrement was still found eight hours
post 0.08% BAC, and an ethanol effect on the vestibular
and visual systems has been shown to persist for up to
several days after BAC returned to zero (reviewed in
[5]). Additionally, two studies [4,6] found that testing
at eight hours post 0.1 or 0.08% BAC showed variabil-
ity in performance suggesting a range of susceptibility
to ethanol. The authors suggested that an arbitrary
eight hour flying prohibition does not take into ac-
count the amount consumed or individual differences
in metabolism and recovery.
General (private) aviation accounts for more than 90%
of all aviation accidents [7]. For the period 1994–2000,
11.5% of alcohol-related general aviation crashes were
linked to a pilot with a DWI (driving while intoxicated)
history [8]. No routine alcohol testing is required for
general aviation pilots. The level of fatal general avi-
ation crashes attributed to alcohol impairment has
decreased from 30% of pilots with a BAC ≥0.04% in the
early 1960s to 8% in the 1990s [9]. However, a study of
alcohol-related fatal crashes between 1985 and 2000 in
Maryland, New Mexico, and North Carolina showed
that 11% had positive BACs and 6% had BACs exceed-
ing 0.04% [10]. The FAA Toxicology and the Document
Information Workflow System databases contain records
of the 2391 certified pilots involved in fatal accidents forthe period 2000–2007. These records show that 215
pilots tested positive post-mortem for alcohol and had
drug or alcohol offenses. Twenty-three of the 215 were
confirmed to have consumed ethanol prior to the fatal
incident. In eleven of these cases, the National Trans-
portation Safety Board linked the accident cause to
alcohol impairment [11]. These studies suggest that in
general aviation, flight impairment due to alcohol con-
sumption is still a safety concern.
FAA forensic toxicological testing detected ethanol
above the legal cutoff of 0.04% in 7% of fatal general
aviation accidents during 2000–2007 [11]. To differenti-
ate antemortem from postmortem alcohol in positive
cases, the FAA (as of November, 2012) uses either the
standard practice of tissue distribution ratios of alcohol
present in blood, vitreous humor, and tissues or, if
urine is available, the ratio of the serotonin metabolites,
5-HTOL and 5-HIAA [12,13]. Unfortunately, in appro-
ximately 30% of ethanol-positive cases, distribution
ratios are inconclusive and FAA toxicologists are unable
to differentiate between ingested and other sources of
the detected ethanol (R. Lewis, personal communica-
tion, November 14, 2012).
Ethanol ingestion impacts human metabolism, lower-
ing blood glucose by stimulating the glucose-stimulated
insulin early secretion response, which can result in a
transient hypoglycemia [14]. Metabolism of ethanol
occurs primarily in the liver and results in production
of intermediate acetaldehyde and then acetate, which
can be utilized by other tissues. This oxidation results
in a decrease in the NAD+/NADH ratio (reviewed in
[15]). Ethanol exposure increases the level of reactive
oxygen species (ROS) in part because of the shift in
NAD+/NADH ratio and the action of cytochromes
p450 and CYP2E1 [16].
The impact of acute ethanol consumption on the innate
immune system and inflammation is well-documented and
includes suppression of proinflammatory cell activation in
a dose-dependent manner [17]. Nuclear factor κB (NF-κB)
is a central mediator of the innate immune response [18]
whose activity is reduced in the presence of ethanol, in
turn affecting levels of pro-inflammatory cytokines, TNF
and IL-1B at the transcription level [19,20].
A major kinase signaling cascade is anchored by the
p38 mitogen activated protein kinase (MAPK). It is
activated by a variety of stressors and inflammatory
cytokines [21]. p38 MAPK regulates a diverse set of
downstream transcription factors, pathways, and cell
functions including cytokine production, cell prolife-
ration, differentiation, and apoptosis including tran-
scription activity of NF-κB. Acute ethanol exposure
has a negative affect on p38 MAPK activity, leading to
decreased NF-κB transcriptional activity, lower levels of
TNF and of proinflammatory cytokine production [22,23],
Kupfer et al. BMC Medical Genomics 2013, 6:26 Page 3 of 16
http://www.biomedcentral.com/1755-8794/6/26and, ultimately, neutrophil and granulocyte migration to
sites of inflammation [17]. Conversely, ethanol induces
oxidative stress by increasing levels of ROS ([16] that can
enhance p38 MAPK activity. p38 MAPK phosphorylates
p300, which in turn acetylates the RelA component,
increasing NF-κB transcription activity [23]. Cytochrome C
and calcium are inter-organellar messengers of apoptosis
(reviewed in [24]). The p38 MAPK pathway is linked to
apoptosis through ROS, mediating mitochondrial dysfunc-
tion, triggering the release of cytochrome C, followed by
calcium release from the ER [25].
Transcription factor STAT3 phosphorylation increases
in the presence of acute ethanol because of increased
activity of Src kinases [26]. IL-10, an anti-inflammatory
cytokine, is a target of the src-STAT3 pathway and shows
an increase in transcription in the presence of acute
ethanol [19]. STAT3 also is an activator of Suppressor of
Cytokine Signaling 3 (SOCS3), and SOCS1, negative
regulators of cytokine signaling [27]. Additionally, acute
ethanol exposure has been shown to have a reproducible
and negative affect on the ability of both monocytes and
dendritic cells to stimulate T-cell antigen presentation
function [28].
Our approach for this study was to evaluate changes
in gene expression levels, using RNA extracted from
whole blood, across a five-point time course as ethanol
entered the blood system, reached a level of 0.08 g/dL
(0.08% BAC), and returned to 0.02% BAC, the lowest
concentration of breathalyzer detection. By microarray
analysis, we examined gene expression changes and
evaluated the resulting genes of interest (GOIs) for
ethanol-related biological relevance, identifying sets




Nine age-matched subjects for the ethanol study were
recruited by D. L. Strayer, Department of Psychology,
University of Utah, Salt Lake City UT. Institutional
Review Board approval to perform research on human
subjects was gained from boards at both the University
of Utah and the FAA Civil Aerospace Medical Institute
(CAMI). The study was conducted at the Department of
Psychology, Salt Lake City, Utah. Informed consent was
obtained by investigators at the Department of Psycho-
logy. The control experiment to establish the effects of
drinking orange juice only was conducted at the CAMI.
Five age-matched male subjects were recruited at the
University of Central Oklahoma. Institutional Review
Board approval was granted from boards at both the
University of Central Oklahoma and the CAMI. Informed
consent was obtained by investigators at the CAMI for the
five subjects.Sample collection and preparation
Subjects drank 125 mL of an orange juice and 80 proof
vodka mixture calculated to achieve a blood alcohol con-
centration of 0.08% wt/vol [29]. Blood Alcohol Concentra-
tions (BACs) were verified using infrared spectrometry
breath analysis (Intoxilyzer 5000, CMI Inc; Ownsboro, KY,
[30]). Blood samples were collected into PAXgene™ Blood
RNA tubes (Cat. # 762165, Qiagen US; Valencia, CA) at
five time points corresponding to BAC, baseline = BAC1,
0.04% = BAC2, 0.08% = BAC3, 0.04% = BAC4 during recov-
ery, and 0.02% = BAC5, this last point being the lower limit
of quantitation by the Intoxilyzer. Control experiment
samples were collected from subjects at time points corre-
sponding to the average collection time for the alcohol
group: T1 was taken prior to drinking 125 mL of orange
juice (OJ), T2 at 90 minutes; T3 at 2 hours, 49 minutes; T4
at 5 hours, 8 minutes; and T5 at 7 hours, 8 minutes.
For the alcohol group, two blood samples were
collected at each timepoint. Total RNA was purified
using the PAXgene™ RNA purification system with the
optional on-column DNase treatment (Cat # 762164;
Qiagen; Hilden, Germany) [31], and stored at −80°C. A
modification in the manufacturer’s published protocol
pooled the two samples from each subject timepoint at
the column binding step such that total RNA was puri-
fied from one PAXgene™ column. A single blood sample
was obtained from each control group subject for each
timepoint in a PAXgene™ Blood RNA tube and purified
according to the manufacturer’s published protocol with
the on-column DNase step.
RNA quality was assessed on an Agilent Bioanalyzer
2100 (Agilent; Santa Clara, CA) using the Agilent RNA
6000 Nano Series II kit following manufacturer’s direc-
tions with 1 μL of sample and the 2100 Expert software
(ver. B.02.03.SI307). Yield and A260/280 was deter-
mined on a Nanodrop 1000 spectrophotometer (Thermo
Scientific; Waltham, MA) (Additional file 1).
Samples from six male subjects (S8, S13, S15, S17,
S18, and S19) were used in the ethanol microarray study
and samples from one female (S1) and 5 male subjects
(S5, S10, S13, S17, S19) were used for qRT-PCR valid-
ation of microarray results.
Microarray target material was made using the One-
cycle IVT kit (P/N 900431; Affymetrix Inc.; Santa Clara,
CA) and the resulting amplified cRNA hybridized to
Affymetrix HGU133plus2.0 GeneChips® according to the
manufacturer’s instructions. One sample, S18-BAC4 was
excluded from further analysis due to a low percent
present call with MAS5.0 (Affymetrix Inc.; Santa Clara,
CA) and insufficient RNA to repeat the amplification/
hybridization leaving 29 samples and arrays.
Total RNA from the five orange juice (OJ) Control
subjects was used to derive target material using the
Ovation 3’ kit (P/N 2200, NuGen Technologies; San
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hybridized to Affymetrix HGU133plus2.0 GeneChips®.
Data handling and analysis
To assess quality and variability in the microarray
data, CEL files underwent standard QC analysis using
the Affymetrix™ GeneChip Operating Software, GCOS
(Affymetrix Inc.; Santa Clara, CA), including a percent
present determination using MAS5.0 (Affymetrix Inc.; Santa
Clara, CA) as noted in the section above. For the ethanol
subjects, CEL files were imported into S +ArrayAnalyzer™,
version 2.1.1 (Tibco Software Inc.; Palo Alto CA),
summarized and quantile normalized using both RMA
[32] and GCRMA [33] algorithms. RMA summarized data
was filtered for log2 (RMA expression) >6 in at least six
arrays; GCRMA, summarized data were filtered for log2
(GCRMA expression) >5 in at least six arrays. The Local
Pooled Error T-test, LPE, [34] was used to test for
significance of differential gene expression across all
possible pairwise comparisons in both sets of summarized
data. Probe sets with p < 0.05 after False Discovery Rate
correction by the method of Benjamini and Hochberg [35]
were further filtered for a fold change greater than 1.25 in
at least one pairwise comparison.
RMA summarized data were used for analysis using
Extraction and Analysis of Differential Gene Expres-
sion, EDGE [36] and the timecourse package [37] in
Bioconductor [38]. The EDGE output was filtered for
probe sets with q < 0.02, the EDGE-specified cutoff. From
the timecourse analysis, the ranked T2 test scores were
visualized as a histogram. Based on a leveling off of the
histogram as scores reached 50, probe sets with ≥50 were
considered the Timecourse50 list. This list was added to
the lists derived from LPE testing and EDGE for further
analysis. Duplicate probe sets and those with the
Affymetrix x_at designation were removed and where a
gene was represented by multiple probe sets, the probe
set with the greatest fold change was retained.
CEL files from OJ Control samples were analyzed using
the same three methods: LPE, EDGE and timecourse.
Since the control subjects were not the same as the etha-
nol subjects, to generate a comprehensive list of genes
and functional pathways responding to orange juice alone
thereby minimizing false positives in the alcohol-
responsive gene list, a significance score of T2 ≥ 25 was
applied to the timecourse analyzed control data. Probe
sets found on both the ethanol and OJ lists were removed
from the alcohol list.
qRT-PCR validation of genes across a range of fold-
changes was used to refine endpoint settings for all
three analysis methods (Results and see below). Cutoff
limits were set at 1.53 fold-change for LPE derived
genes, q ≤ 0.0017 EDGE derived genes and T2 > 82.83
for timecourse derived genes resulting in a list of 203probe sets for further analysis. To cluster probe sets
by temporal expression pattern, Z-transformed expres-
sion values for the probe sets were used as input for
K-means fuzzy-clustering [39].
The entire probe set list and the individual expression
pattern-clustered probe sets, were analyzed with
Ingenuity Pathway Analysis, IPA (version 8.7, Ingenuity®
Systems, Inc., www.ingenuity.com; Redwood City, CA)
and the Database for Annotation, Visualization, and
Integrated Discovery, DAVID [40]. The BioGPS database
was used to evaluate tissue-specific gene expression using
the Human U133A/GNF1H Gene Atlas dataset,
(GEO-GSE1133, [41,42] ). The BIOBASE [43] ExPlain™
[44] Mammalian Module 3.0 was used with the applica-
tion Match™ to examine the promoter regions of the
cluster genes for transcription factor binding matrices
using the BIOBASE TRANSFAC® database. The RMA
summarized data set filtered for average log2 (expres-
sion) > 6 and with the 203 candidate genes removed
was used for the No-set (background). The verte-
brate_h0.01 profile was used. High-specific matrices with
cut-offs minFP were used for a 1200 base promoter
window from −1000 to 200. Both cut-off and window
position were optimized with a p-value threshold of
0.001. The Match matrix output was filtered for a Yes/No
ratio of >1.5, P-value <0.01 and Matched promoters P-
value <0.01. The weight matrices profile was used to
create a transcription factor gene set and filtered for
human specific factors. The gene set was mapped on
canonical pathways using the BIOBASE Transpath ap-
plication using P-value <0.01, minimal hits to group of
two. A Transpath gene set linking the transcription fac-
tors to pathways was generated for each cluster. The
resulting output was examined for signaling pathways
and transcription factors predicted to affect genes on
our list. Figure 1 shows the analysis pipeline.
The microarray data is publicly accessible and has
been assigned series number GSE20489 in the Gene
Expression Omnibus (GEO) [45] and can be freely accessed
from their website.
Quantitative PCR
Fifty nanograms of total RNA from each of six ethanol
subjects, S1, S5, S10, S13, S17, and S19, were reversed
transcribed and amplified for use with qRT-PCR with
the Ovation 3’ amplification kit (P/N 2200, NuGen
Technologies; San Carlos, CA) according to the manu-
facturer’s protocol. Candidate GOIs for qRT-PCR were
chosen from the EDGE-generated list (IMPA2, TMEM8
and CDA) and from the pooled LPE list (ANKRD28,
EVI2A, FKBP5, LR8). The final GOI, RNF11, was on
both lists.
Candidate normalizer genes were filtered from RMA-
summarized, non-normalized microarray expression data
Microarrays across time points
Quantile normalization
Filter for expression change >=1.25 fold
One or more contrast
IPA
Selected qPCR validation 
and cutoff
Summarization















Figure 1 Microarray data analysis pipeline. Analysis pipeline for
control and ethanol exposed microarray data sets.
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expression >5.5 across all 29 chips and further refined
with the analysis tools NormFinder [46] and geNorm
[47]. geNorm pairwise variation showed that three
normalizers were sufficient for the study. The three
genes selected, ITGA5, SCAMP2, and PLCG2, had
NormFinder stability rankings in the top 20% of the
candidates, 0.045, 0.045 and 0.048, respectively, and are
functionally non-redundant. Genes with better stability
rankings were not good candidates for primer design.
Primers for both normalizer genes and GOIs were
designed for detection by SYBR-Green using Beacon De-
signer 7.0 (PremierBiosoft; Palo Alto, CA) (Additionalfile 2) and obtained from Integrated DNA Technologies
(Coralville, IA). Primer pairs were rigorously screened for
qRT-PCR reaction efficiency greater than or equal to 93%
and the presence of a single product by electrophoresis
on a Bioanalyzer DNA 1000 chip (Agilent; Santa Clara,
CA). qRT-PCR was performed on a MX3005P cycler
(Stratagene; La Jolla, CA) using Platinum SYBR-Green
qRT-PCR SuperMix UDG (P/N 11733046, Invitrogen;
Carlsbad, CA) in 25 μL reactions according to the enzyme
manufacturer’s recommendations and optimal primer
annealing temperature for each primer pair. A noRT ex-
periment with TMEM8 revealed all samples had 10 Cts or
greater difference compared to the experimental samples.
Differential expression analysis of qRT-PCR data was
performed with REST2009 [48] after normalization to the
geometric mean of normalizer expression values.
Results and discussion
Microarray data analysis and candidate gene list
derivation
We report microarray derived gene expression changes
over a BAC profile to a maximum of 0.08% after ingestion
of an alcohol cocktail of orange juice (OJ) and vodka. A
control group was administered only orange juice to distin-
guish genes and biological pathways responding to the OJ
from those responding to the alcohol. Five samples were
taken from each subject (BAC1-5), a baseline sample and
then at BAC levels, or for the control group, the time
matched equivalent, of 0.04%, 0.08%, and recovery samples
at 0.04% and 0.02%, the lowest concentration detectable by
breathalyzer (Methods).
Because the experimental conditions were performed
with different groups of subjects, we used a conservative
analysis model that included three microarray data analysis
tools - LPE t-test [34], EDGE [36] and timecourse [37]
(Methods) - to identify candidate genes. The LPE t-test
was applied across all 10 possible pairwise timepoint
comparisons and the lists of significant probe sets pooled.
From the ethanol data, the LPE list contained 171 probe
sets, the EDGE list 63 probe sets, and the Timecourse50
list 452 probe sets.
When applied to the OJ data, the LPE t-test found 22
differentially expressed probe sets, one of which was in
common with the ethanol list. The EDGE analysis found
no significantly changing probe sets. In the timecourse
analysis, 23 probe sets above the test score cutoff of 25
were found in common with the ethanol list. These 24
probe sets were removed from the ethanol list. The 19
genes represented by these probe sets were examined in
DAVID and IPA to determine pathways responding to OJ.
GO_FAT results from DAVID showed that eight genes are
involved in translation and translation elongation. There-
fore, the “protein translation” biological process was not
considered in further analysis of the ethanol data.
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values
qRT-PCR was used to validate the microarray results for
direction and fold-change across the experiment. Four
genes were selected from the LPE list: ANKRD28, EVI2A,
FKBP5, LR8, and the EDGE list: IMPA2, TMEM8, CDA
and RNF11 (Table 1). Only ANKRD28 and LR8 were not
on the Timecourse50 list. ITGA5, SCAMP2 and PLCG2
were selected as normalizers based on microarray expres-
sion data across all 29 chips (Methods).
Comparisons across all 10 possible pair-wise BAC
contrasts were performed using Relative Expression
Software Tool, REST ([48], Methods). The direction of
change was found to be the same for the microarray and
qRT-PCR results with the single exception of the BAC 4
versus 5 contrast for ANKRD28, where the microarray
results showed an increase rather than the decrease seen
in the qRT-PCR comparison (Table 2); however, this was
not a statistically significant contrast in the LPE t-test
(Table 1).
With two exceptions, all other statistically significant
contrasts from microarray data were validated by qRT-
PCR. LR8, significant in a single contrast at a fold-
change level of 1.25 (Table 1), could not be confirmed,






201389_at ITGA5 0.0063 312 NA^
204613_at PLCG2 0.0648 2817 NA
218143_s_at SCAMP2 0.0161 829 NA
LPE selected genes
226025_at ANKRD28 0.0114 563 0
204774_at 0.0452 2135 0.021
0
0
224840_at FKBP5 0.0347 1715 0.009
0.044
0.025
220532_s_at LR8 0.287 9699 0
EDGE selected genes
203126_at IMPA2 0.0013 3 NA
221882_s_at TMEM8 0.0013 6 NA
205627_at CDA 0.0013 11 NA
208924_at RNF11* 0.0017 51 0.006
*RNF11 is found on all three lists.
^NA Not Applicable, P-value > 0.05, not on gene list for given analysis method.
Bold-Not on the TIMECOURSE50 list.significant contrasts (BAC2 vs. 5, Table 1). Therefore, for
further characterization of the biological response to
ethanol, the limit of detection for genes coming from
the LPE analysis was set at a fold change of 1.53, based
on confirmation of FKBP5 (Tables 1 and 2). Likewise,
based on the observation that the largest q-value from
the EDGE analysis that could be validated by qRT-PCR
was 0.0017, the gene list was filtered to remove EDGE-
list genes above that level. Similarly, the lowest validated
timecourse score was 82.83, based on IMPA2 (Table 1).
Genes below this level were removed. The resulting
merged list from the three analyses contained 203 GOIs.
Functional analysis of the genes of interest (GOIs)
To obtain an overall picture of pathways that respond to
ethanol ingestion, the complete list of 203 GOIs was
assessed using IPA. Functional categories included immune
and inflammatory response, hematological system develop-
ment and function, hepatic system disease, carbohydrate
metabolism, cell death, cell-cell signaling, and nucleic acid
and amino acid metabolism. Using DAVID, the GOIs clus-
tered into functional categories including immune system
development, protein catabolism, and S100A EF hand pro-
teins. An examination for over-represented GO terms from
DAVID in the candidate gene list identified 21 genes withLPE Timecourse
roarray fold
change







1.689 BAC 2 vs 5 25.97
1.45 BAC 2 vs 5 95.59
1.64 BAC 3 vs 4
1.95 BAC 3 vs 5
−1.54 BAC 1 vs 4 326.231
−1.53 BAC 1 vs 5
−1.57 BAC 2 vs 4




1.76 BAC2 vs 5 208.403
Table 2 qPCR relative expression ratios between BAC points
Timepoint comparison
GOI BAC1-2 BAC1-3 BAC1-4 BAC1-5 BAC2-3 BAC2-4 BAC2-5 BAC3-4 BAC3-5 BAC4-5
EVI2A −1.7 −2 1.76 1.63
RNF11 −1.45 1.981 1.87 1.808 1.35
ANKRD28 1.477 2.282 1.671 1.72 −1.435
FKPB5 −1.65 −1.439 −1.5 −1.58
TMEM8 −1.4 −1.432
CDA −1.42 −1.67 −1.55 −1.35
IMPA2 −1.28 −1.34 −1.3 −1.309
LR8
GOI, Gene of interest.
BAC, blood alcohol concentration, refers to the level of alcohol present in subject at time of blood sampling, see M&M.
A negative value means a decrease in relative expression for the second timepoint relative to the first.
Bold-direction of change disagrees with microarray analysis.
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innate immune response.
To further examine the temporal response to ethanol
exposure, we clustered the GOIs by expression pattern.
Seven clusters were formed by 199 of the genes; four were
unclustered. The seven clusters were analyzed using IPA,
BIOBASE, and BioGPS (Figure 1 and Methods).
Cluster 1
Genes in this cluster exhibit a decreased expression level
at BAC4 followed by a sharp increase at BAC5 (Figure 2),
suggesting that these genes constitute a late response of
increased expression well after alcohol levels begin to
decrease. Of the 23 genes in Cluster 1, IPA created a sin-
gle network from 14 members with the top biological
functions of Infectious Disease, Cell Signaling, and Small
Molecule Biochemistry (Table 3).
Interactions within the network include RIOK3, a GOI
that regulates NF-κB [49], which in turn interacts with
the GOIs BAX, a blood exclusive, stress-induced pro-
apoptotic factor [50], UBR5 the E3 ubiquitin ligase
linked to apoptosis [51], and KLF3, a hematopoietic tran-
scription factor important in apoptosis and the inflamma-
tory response [52]. Transcription regulator TP53 levels are
regulated by the GOIs UBE2D3, an E2 ligase [53], BAX,
and the proteoglycan VCAN, important in cell adhesion
[54]. Other GOIs in the network include the lysosomal
marker LAMP1, important for protein trafficking [55],
ACTR2, essential for cell shape [56], the cytokine regulator
CNPY3 [57], PF4V1, a hematopoietic chemokine and
histone methylation factor [58], and MPHOSPH8 a tran-
scription regulator involved in DNA methylation [59].
Transcription Factor Binding Site (TFBS) analysis with
BIOBASE found binding sites for NF-κB in BAX, KLF3,
UBE2D3, and PF4V1. LAMP1, ACTR2, and the poorly
annotated genes TMEM165 and MGC2752 containbinding sites for the ETS protein SPI-1, important in
lymphoid and B-cell development ([60,61]. The BIOBASE
analysis reinforces the NF-κB link detected in IPA and
implicates the p38 MAPK pathway and its regulation of
NF-κB (Figures 3 and 4).
Cluster 2
Cluster 2 genes increase expression at BAC 3, 4, and 5
from BAC 1 or 2 with no return to baseline (Figure 2).
IPA created a single network that includes 40 of the 44
genes in the expression cluster. Top network functions
are Cellular Assembly and Organization, DNA Replica-
tion, Recombination and Repair, and Cell Cycle (Table 3).
Insulin, a key sensor of glucose levels, is found in this
network with connections to the GOI PDP1, an activator
of pyruvate dehydrogenase [62], and PIKFYVE, a mem-
ber of the inositol phosphate metabolism pathway under
positive regulation by insulin [63]. Pro-inflammatory
cytokine, IL-6, is a central non-GOI member of the
network linked to insulin and regulating GOIs TBC1D9,
a GTPase factor expressed in dendritic cells [42], BMI1, a
factor in stem-cell pluripotency [64] and PARP8, involved
in post-translational modification [65]. The heterotrimeric
GTPase subunit GNAQ impacts the ERK and Akt signaling
pathways. HNF4A, a non-GOI transcription factor regulat-
ing genes involved in glucose metabolism and homeostasis
[66], has direct protein-DNA interaction with the GOIs
SEC23A, an ER-Golgi trafficking molecule [67] known to
be positively regulated by insulin [68], TMEM30A, also
involved in protein exit from the ER [69], NEK7, a mitotic
regulator [67], the TGFB1 receptor, TGFBR1 and BMI1.
NF-κB, another central non-GOI in this expression cluster,
interacts with or regulates the GOIs, BMI1, GNAQ, the
ER-aminopeptidase, ERAP2, and TGFBR1 (Figure 4). The
non-GOI cytokine TGFB1 interacts with the aforemen-
tioned receptor TGFBR1, and BMI1.
A. 
Down at 4 up at 5 toward or 
above baseline
B. 
Up from 2, no return to baseline
C. 

















Down at 2, up 3, 
no return to baseline
E. 
down at 2 no return to baseline
F. 
Up at 4 down 5 toward or 
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Up at 4 and 5
BAC point


























































































Figure 2 Expression pattern clustering. Each panel A-H shows the expression pattern for individual members of each gene cluster based on
microarray expression data for the gene probe sets at each of the five BAC points. A. Cluster 1, 23 members with expression pattern down at 4
up at 5 toward or above baseline. B. Cluster 2, 44 members with expression pattern up from 2, no return to baseline. C. Cluster 3, 47 members
with expression pattern down at 2, up to or above baseline at 5. D. Cluster 4, nine members with expression pattern down at 2, up 3, no return
to baseline. E. Cluster 5, 67 members with expression pattern down at 2 no return to baseline. F. Cluster 6, four members with expression pattern
up at 4 down 5 toward or to baseline. G. Cluster 7, five members with expression pattern up at 4 and 5. H. Unclustered, four genes which did
not fall into any cluster. Percent blood ethanol concentrations, BAC1 = 0%, BAC2 = 0.04%, BAC3 = 0.08%, BAC4 = 0.04%, BAC5 = 0.02%.
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binding matrix for ATF2 and/or CREB1. Phosphorylation
of both is regulated by p38 MAPK [70,71]. Three
blood or dendritic cell-specific genes carry a matrix
binding only CREB1 ([42], Figure 3). This analysis
also identified four GOIs which bind interferon regu-
latory factors 3 and 7 (IRF3 and IRF7), members of
the Toll-like receptor 4 (TLR4) pathway (Figure 3).
In summary, genes in Cluster 2 are influenced by
insulin and co-regulated by factors in the p38 MAPK
signaling pathway.Cluster 3
The expression patterns of Clusters 2 and 3 are similar;
Cluster 3 exhibits an immediate-early decrease in expres-
sion from BAC1 to BAC2 not seen in Cluster 2 (Figure 2),
followed by increasing expression levels through BAC5.
IPA analysis of genes in Cluster 3 resulted in a network
containing 36 of the 47 members (Table 3). Transcription
factor HNF4A seen in the Cluster 2 network is found here
linked to six GOIs, RASA1, which promotes cell migration
and adhesion [72], RORA, a T-cell specific factor [73],
CUL5, a cullin expressed in lymphocytes [42], DCK,
Table 3 Ingenuity pathway analysis* results
Input Target genes Target members Score-log p-value Network functions
Cluster 1 23 14 37 Infectious Disease, Cell Signaling, and Small Molecule Biochemistry
Cluster 2 44 40 94 Cellular assembly and Organization, DNA Replication, Recombination
and Repair, Cell Cycle, Immune Deficiency
Cluster 3 47 36 78 Cell-To-Cell Signaling and Interaction, Small Molecule Biochemistry
Cell Cycle, Cellular Function and Maintenance, Hematopoiesis and
Hematological System Function
Cluster 4 9 7 13 Cell Death, Small Molecule Biochemistry Infectious Disease Response,
Cellular Growth and Proliferation
Cluster 5 67 39 78 Immune Cell Trafficking, Hematological system Development and
Function, Apoptosis, Cell signaling, Small Molecule Biochemistry
20 32 Cellular Growth, Proliferation and Development, Gene Expression
Carbohydrate Metabolism
Cluster 6 4 2 7 Immune response
Cluster 7 5 4 11 Gene Expression
*Ingenuity Pathway Analysis Ver 14197757, Ingenuity Systems Inc.
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http://www.biomedcentral.com/1755-8794/6/26expressed in whole blood and lymphocytes [42],
GFM1, a mitochondrial translation elongation factor
[74], and PKA, a cellular effector of cAMP [75]. The
network also includes the two GOI integrins posi-
tively regulated by calcium ion and TGFB1, ITGA4, and
ITGB1, components of the innate immune response
(reviewed in [76]).
BIOBASE analysis associated six Cluster 3 GOIs with the
p38 pathway through JUN and two transcription factors
detected in Cluster 2, CREB1 and ATF2, which can
heterodimerize with JUN (Table 4). These GOIs include
ZNF12, a transcriptional repressor of AP-1 [77], DNAJB14,
RORA, CUL5, LYRM7, and PRKACB.
Transcription factor SPI-1, an effector of p38 MAPK
signaling ([78], Table 4), regulates seven Cluster 3 GOIs,
RORA, DNAJB14, DOCK10, a factor induced by IL-4 in
B lymphocytes [79], SP4 a transcription factor that regu-
lates NF-κB [80], two ubiquitination factors, USP1 and
RNF6, and vacuolar protein VPS13C.
Binding sites for E2F family transcription factors are
found in FECH, which catalyses the last step in heme
biosynthesis [81], MBNL1, linked to insulin receptor spli-
cing [82], UBE2J1 a dendritic cell-specific [42] ubiquitin
conjugating enzyme HLTF, a transcription factor regulating
cytokine production [83], PRKD3 a B cell protein kinase
[84], FAM46C and FAM3C cytokine-like factors [85] and
SP4, DOCK10, ITGB1, ITGA4 and RORA, five factors
mentioned previously. Fifteen Cluster 3 GOIs contain
TCF/LEF binding sites. This Wnt-regulated group includes
three factors involved with mRNA maturation, RASA1,
SFRS7, NUDT21, and three involved with protein modifi-
cation or degradation, ZDHHC2, MGAT4A, and YOD1.
Cluster 4
These nine genes exhibit an immediate-early response,
sharply decreasing in expression from baseline to BAC2,and then moderately increasing at BAC3 (Figure 2). Two
of these genes have not been characterized (Additional
file 3). The remaining seven genes form a single IPA net-
work with functions including Cell Growth and Prolifera-
tion, and Small Molecule Biochemistry that contains TP53
and NF-κB as central non-GOIs. Within this cluster, the
NF-κB inhibitor, NFKBIA, and the pro-inflammatory
calcium-binding protein S100A12 are found highlighting
the delicate interplay in regulatory control of NF-κB ac-
tivity. Also in this cluster are MED6, a member of the
Mediator complex [86], and PADI4, a gene that plays a
role in granulocyte and macrophage development in in-
flammation and the immune response [87].
From BIOBASE, p38 MAPK is implicated in the regula-
tion of Cluster 4 immediate-early response genes through
binding sites for the JUN/ATF2 heterodimer in the PADI4
and S100A12 genes, and ELK1 binding to PHC2, NFKBIA,
and MED6. In addition, BIOBASE also associated Cluster
4 GOIs PHC2, MED6, GPSM3, PADI4, NFKBIA with the
apoptosis signaling pathway through binding matrices for
ELK-1, FOXO3 and 4, and MYC (Table 4), of which four
are shared with p38 MAPK signaling (Figure 3). PHC2 is
highly expressed in whole blood and can associate with
BMI1 a GOI factor in Cluster 2 associated with cell di-
vision in hematopoietic stem cells [88]. GPSM3 is unique
in containing only a FOXO3 binding site.
Cluster 5
This is the largest expression cluster, containing 67 early
response GOIs with a distinctive decrease in expression
from BAC2 to BAC5 (Figure 2). Due to computational
limitations in network size, IPA created two networks
that could be merged. Examination of the merged
network reveals central non-GOIs that include NF-κB,
p38 MAPK, insulin, IL-1, -6, and −12, TNF, TGFB1, and
d-glucose as an activation agent. The functions assigned
Figure 3 BIOBASE-derived signaling network centered on p38 MAPK. Summarized BIOBASE analysis results for the GOI clusters. Red circle, p38
MAPK, red molecules directly linked to the p38 MAPK pathway are BIOBASE-identified transcription factors, other red molecules GOI transcription factor
targets. In yellow are non-p38 MAPK pathway transcription factors and their target GOIs. In orange are transcription factors and GOIs shared by more
than one pathway. Blue indicates ethanol and ROS (reactive oxygen species). Interaction labels: A activation, P phosphorylation, T transcription.
Legend: shapes define molecule types and interactions.
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Figure 4 GOI links to NF-κB determined through the analysis. Gray
non GOI factors, blue outlined Ethanol and Reactive Oxygen Species,
red p38 MAPK, pink NF-κB. Other colors indicate GOI cluster
membership. Purple is Cluster 1, yellow Cluster 2, turquoise Cluster 3,
orange Cluster 4, blue Cluster 5, green Cluster 7. Arrows indicate
activation and direction of effect, Bar indicates inhibition and direction
of effect, Interaction labels: A, activation, P phosphorylation, T
transcription, E expression, PP protein-protein binding, S secretion, LO
localization. Legend: shapes define molecule types and interactions.
Table 4 Pathway-specific transcription factor profile
A. p38-related TF* profile by cluster
Cluster 1 2 3 4 5
Transcription NF-κB NF-κB





B. Cluster-specific TF pathway profiles
Cluster 2 3 4 7
Pathway
Membership










*TF Transcription factors predicted by BIOBASE [43] to bind cluster members
as defined in the text.
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mune Cell Trafficking, Hematological System Function,
and Apoptosis and for Network 2: Cell Growth, Prolifera-
tion and Development, Gene Expression, and Carbohy-
drate Metabolism (Table 3).
Cluster 5 contains three members of the pentose phos-
phate pathway (PGLS, TALDO1, TKT), which is inhibited
in the presence of ethanol [15]. GOI IMPA2 is important
in phosphatidylinositol and insulin signaling [89]. Four
members of the S100A calcium binding family are mem-
bers of Cluster 5 and are network targets of TGFB1. Add-
itionally in the network, S100A4 is regulated by the NF-κB
complex, ERK and AP-1; S100A9 is regulated by P38
MAPK, and S100A6 is linked to activation of JNK, which
in turn is integral to IL-1 and IL-12 signaling [20].
BIOBASE analysis linked 44 Cluster 5 genes to the
p38 MAPK signaling pathway through binding sites for
transcription factors ELK-1, CREB1, NF-κB, and SPI-1
(Figure 3). Most have binding sites for more than one of
these factors. However, seventeen of the 44 contain onlySPI-1 binding sites and function in defense response, the
pentose phosphate shunt, inositol phosphate signaling,
and S100A signaling.
Cluster 6
These four genes constitute a late-response cluster
specific to falling ethanol levels with an expression spike
at BAC4 and return to baseline at BAC5 (Figure 2). IPA
put two of the four members, HLA-DQA1 and HLA-
DQB1, the subunits of the DQ heterodimer and compo-
nents of major histocompatibility complex CII [90] in an
immune response network. GIMAP2 and MXRA7 were
not assigned to a network. GIMAP2 is uniquely expressed
in whole blood and T-cells [42], and is a GTPase in the
immunity-associated protein family [91]. MXRA7 is a ubi-
quitously expressed gene with unknown function.
Cluster 7
These five genes show a delayed response, increasing in
expression levels at BAC4 and 5 as ethanol levels de-
crease. Four of the five genes appear in an IPA network
with gene expression as the top function. HMGB1
(amphoterin), is a cytokine mediator of inflammation
[92] through RAGE ([93], Figure 4). Also in this network
are UBA6, regulated by TNF and INF-gamma [94],
RGS18, a whole blood-specific [42] G-protein signaling
attenuator [95], PPP4R2, involved in the maturation of
splicosomal snRNPs [96]. EVI2A is an uncharacterized
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specific expression [42]. Cluster 7 members regulate a
range of cellular mechanisms, including protein recycling
[94], signal transduction [95], immuno-modulation [92],
and transcript maturation [96].
BIOBASE analysis showed that HMGB1 carries bind-
ing sites for STAT1, 3 or 5A. STAT1 can form homo- or
heterodimers [97] with STAT3, which is also upregulated
by acute ethanol exposure as part of the Src pathway
[26]. STAT5a, an antiapoptotic factor [98], shows cell-
specific response to ethanol, is up-regulated in T cells
and down-regulated in NK cells and induced by a num-
ber of cytokines [99]. HMGB1 is an antiapoptotic factor
that binds RAGE to elicit release of cytokines [100,101].
Summary
To identify potential gene expression markers and
increase our understanding of the biological response to
acute ethanol ingestion, we used a microarray and qRT-
PCR-based approach on whole-blood RNA samples
collected from human subjects administered orange juice
with and without ethanol.
Our microarray data analysis revealed biases in the three
analysis methods used. At the qRT-PCR-validated signifi-
cance limits used, the LPE- and EDGE-lists share only one
gene. Timecourse was more comprehensive; this list shared
13 genes with the LPE-derived list and 17 genes with the
EDGE-derived list. This observation extended to the ex-
pression patterns detected upon clustering of the genes.
The LPE t-test uniquely identified 42 of 44 genes in Cluster
2 and 38 of 47 Cluster 3 genes, whereas in Cluster 5, 39 of
67 genes were identified only by EDGE. All of the Cluster
4 and unclustered genes were from the Timecourse50 list.
The explanation of the bias is likely rooted in the nature of
the relative expression change patterns; for example, LPE
was the analysis method that detected the majority of
genes increasing in expression across the experimental
time course. Most importantly all three methods identified
genes that were confirmed by qRT-PCR as differentially
expressed (Tables 1 and 2).
Certain biological regulatory motifs emerged from our
analysis, key among them, calcium flux, the influence of
NF-κB and p38 MAPK.
Calcium binding
There are 16 calcium binding genes in the ethanol GOIs,
as characterized by DAVID (Additional file 3). Notably,
six are members of the S100A family. This is a group of
more than 25 small, acidic, EF-hand (calcium-binding)
proteins. They can form homo- or heterodimers leading
to complex calcium signaling dependent on the available
S100A populations [102]. Four, S100A4, -6, -9, and −11,
are found in Cluster 5, an early response cluster with
decreased expression. S100A12 belongs to Cluster 4and has an immediate early decreased expression
profile. The unclustered S100A8 has an early decrease
in expression but returns to baseline at BAC5. Taken
together, the known decrease in NF-κB mediated inflam-
mation from ethanol [20] could be the result of decreased
S100A4, -6, -11, and −12 binding to the pro-inflammatory
RAGE ([102,93], Figure 4).
Five calcium binding genes showed increased expres-
sion as members of the early response Cluster 2 and
immediate early Cluster 3 (Figure 2). Cluster 2 includes
TBC1D9, linked to hepatic disease [103], PDP1, a regu-
lator of pyruvate levels, GALNT7, a member of the O-
glycosylation pathway [104], and the mannose hydrolase
MAN1A1. Cluster 3 contains ITGA4, an integrin highly
expressed in blood and leukocytes linked to recruitment
of leukocytes to sites of inflammation [105].
It is known that levels of ionized calcium in the blood
decrease in the presence of acute ethanol exposure, and in
rats, the level and duration of the decrease is correlated
with the concentration of ethanol [106]. Decreased calcium
would further modulate inflammation through decreased
S100 protein oligomerization. It is known that in T-cell ac-
tivation, ionized calcium regulates entry into the cell cycle
through the induction of gene transcription by reversing
Rb1 inhibition of E2F factors [107]. We found that E2F
factors were linked to Cluster 3 expression (Table 4) sug-
gesting that the known ethanol-dependent reduction of
ionized calcium levels [106] is acting at the transcription
level to inhibit, then release entry into the cell-cycle.
NF-κB as central regulator
NF-κB is a central regulator appearing in all but one
of the cluster function analyses (Figure 4), indicating
a level of co-regulation linking ethanol ingestion to in-
nate immunity and the inflammatory response. Combin-
ing temporal expression patterns with direct and indirect
molecular interactions defined by pathway analysis, we
hypothesize that NF-κB-regulated inflammation is down-
regulated early and moderates as blood ethanol levels
decrease. The decreasing inflammatory response results
from lower levels of S100A proteins and their effect on
RAGE induction of NF-κB, and RORA activation of
NFKBIA. BMI1 is induced in an immediate early res-
ponse and may counter the decreased inflammatory
response. Evidence for the return to normal levels of NF-
κB activity is in the late increase in expression of S100A8
and Cluster 1 genes KLF3, UBE2D3, and PF4V1, and may
be a result of increased expression of Cluster 7 gene,
HMGB1 (Figure 4) and subsequent activation of RAGE
(reviewed in [108]). Modulating the late increase in NF-κB
activity is BAX, another Cluster 1 gene. NF-κB acts as both
an enhancer and suppressor in the MHC CII promoter
[109], suggesting NF-κB regulation of the expression spike
in the two Cluster 6 MHC CII components.
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BIOBASE is a powerful tool that complements the IPA
analysis by looking for conserved transcription factor
binding sites in the GOIs and moving upstream to iden-
tify significant signaling pathways. Within a 1200 bp
window, several transcription factors were found to bind
to GOI promoters across more than one cluster. SPI-1,
ATF2, and CREB1 are each binding within genes in mul-
tiple but not the same clusters, (Table 4A). ATF2 and
JUN are both found in Clusters 3 and 4, which have
differing expression patterns overall, but share a marked
decrease in expression from BAC1 to BAC2. The shared
ATF2/CREB binding site is found in Clusters 2 and 3
which have similar expression patterns, especially from
BAC2 to BAC5.
The p38 MAPK pathway was identified as a central
regulatory pathway for clusters 1, 2, 3, 4, and 5 (Figure 3).
These clusters have diverse expression patterns likely
reflecting the heterogeneity of cells in whole blood, interac-
tions with various other signaling molecules or tran-
scription factors, and the variability of post-translational
modification, none of which can be detected by BIOBASE.
The p38-regulated functional categories predicted by
BIOBASE include the innate and inflammatory immune re-
sponses, ubiquitination, apoptosis, and energy metabolism.
Unique signaling pathways that may modulate p38
MAPK were predicted by BIOBASE within three clusters
(Figure 3). GOIs within Cluster 2 contain binding sites
for IRF3 and IRF7, which are linked to TLR4 signaling.
TLR4 signaling activates the p38 MAPK pathway and
is especially sensitive to ethanol exposure, exhibiting a
dose-dependent response curve [110].
Binding sites for ETF2 are found within 12 genes in
Cluster 3; these GOIs are involved in ubiquitination and
cytokine production. The binding site for LEF/TCF is
found within 13 GOIs in Cluster 3, in which are also
found binding sites for transcription factors from mul-
tiple signaling pathways that regulate hemoglobin bio-
synthesis and immune response regulation. The apoptosis
network regulated through FOXO3 and 4, and MYC bind-
ing, in concert with p38 MAPK signaling through ELK1, is
unique to Cluster4. Unlinked to p38 MAPK signaling is
STAT signaling found in the delayed response Cluster 7
(Table 4B) and known to be up-regulated in response to
acute ethanol [19,26].
Biomarker identification
Conceptually, markers for ethanol consumption could
be of two types, actual BAC, or impairment. Expression
patterns of the clustered genes neither positively nor
negatively correlate to ethanol concentration; however,
two unclustered genes correlate to BAC more closely,
CRISPLD2 and NUDT4. These two genes have opposite
patterns of expression exhibiting their most extremevariation from baseline to 0.08% BAC and returning to
baseline expression at 0.02% BAC, the last collection
point in this study and are potentially useful markers
for BAC.
For forensic toxicology, impairment is the least under-
stood but most important metric. Here, we have shown
that most of our 203 genes do not return to baseline at
0.02% BAC, suggesting that further efforts should concen-
trate on correlating cognition to expression patterns,
thereby capturing the “hangover” effect. Specifically, several
genes in Clusters 2 such as PDP1, GNAQ and TGFBR1,
and Cluster 5 members like S100A4, -6, and −8 and the
three pentose phosphate shunt members TALDO1, TKT
and PGLS, exhibit expression patterns consistently increas-
ing or decreasing over the entire experimental time-course,
suggesting that they may return to baseline as cognition
recovers. Further effort to determine at what cognitive level
they returned to baseline would be informative. Likewise,
the delayed response genes in Cluster 7 (Figure 2) may be
indicative of cognitive impairment.Conclusions
We determined patterns of gene expression related to
acute exposure to ethanol. Our analysis suggests that we
could detect significant gene expression changes related
to imbibed ethanol using RNA isolated from blood. We
found that members of each cluster were linked by
common biological processes, signaling pathways, and
functions including:
– protein synthesis and modification
– hematological and immune functions, especially
innate immunity
– inflammation
– p38 MAPK and NF-κB signaling
– central metabolism and small molecule metabolism
Additionally, our findings support the workflow des-
cribed here for selecting candidate biomarker genes for
future studies. Those studies would correlate performance
limitations to ETOH-dependent gene expression patterns
and, using currently available toxicological tests to monitor
BAC, must extend beyond the breathalyzer limit of detec-
tion of 0.02%, to capture cognitive “hangover effects”. A
gene expression-based test for ingested ethanol would
provide additional sensitivity in those forensic instances
where standard toxicological tests cannot discriminate
between ingestion and post-mortem ethanol sources. We
further expect that understanding gene expression changes
and their correlation to human performance metrics will
facilitate modification of flight regulations based on increa-
sed understanding of ethanol’s impact on performance
independent of blood alcohol concentration.
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